Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Systemic Retinoids in Cutaneous T-Cell Lymphoma: A Scoping Review of Clinical Use and Evidence Gaps.Dermatology and therapy · 2026Review
- Primary Cutaneous Anaplastic Large Cell Lymphoma: A Review of Diagnosis and Treatment for the General Oncologist.Cancers · 2026Review
- Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review.Frontiers in medicine · 2026Review
- Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.Blood advances · 2025Article
- Pralatrexate for refractory mycosis fungoides in two Japanese patients.The Journal of dermatology · 2021Article
- Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.Pharmaceutics · 2021Review
- Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.Current treatment options in oncology · 2021Review
- Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides.Annals of translational medicine · 2020Article
- Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.OncoTargets and therapy · 2019Review
- Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.Frontiers in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.